Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 8103019, 6 pages
http://dx.doi.org/10.1155/2016/8103019
Research Article

Predictive Significance of Serum Level of Vascular Endothelial Growth Factor in Gastric Cancer Patients

Department of Clinical Laboratory, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing 100142, China

Received 2 June 2016; Revised 12 July 2016; Accepted 12 July 2016

Academic Editor: Mario Scartozzi

Copyright © 2016 Lu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Kamangar, G. M. Dores, and W. F. Anderson, “Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137–2150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Ferlay, D. M. Parkin, and E. Steliarova-Foucher, “Estimates of cancer incidence and mortality in Europe in 2008,” European Journal of Cancer, vol. 46, no. 4, pp. 765–781, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Lee, K. Demissie, S.-E. Lu, and G. G. Rhoads, “Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea,” Cancer Control, vol. 14, no. 1, pp. 78–85, 2007. View at Google Scholar · View at Scopus
  4. R. Rahman, A. W. Asombang, and J. A. Ibdah, “Characteristics of gastric cancer in Asia,” World Journal of Gastroenterology, vol. 20, no. 16, pp. 4483–4490, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. D. J. Park, N. J. Thomas, C. Yoon, and S. S. Yoon, “Vascular endothelial growth factor A inhibition in gastric cancer,” Gastric Cancer, vol. 18, no. 1, pp. 33–42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Ferrara, “VEGF and the quest for tumour angiogenesis factors,” Nature Reviews Cancer, vol. 2, no. 10, pp. 795–803, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. V. P. Chekhonin, S. A. Shein, A. A. Korchagina, and O. I. Gurina, “VEGF in tumor progression and targeted therapy,” Current Cancer Drug Targets, vol. 13, no. 4, pp. 423–443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Werther, I. J. Christensen, H. J. Nielsen et al., “Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma,” British Journal of Cancer, vol. 86, no. 3, pp. 417–423, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Folkman, “Tumor angiogenesis: therapeutic implications,” New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-N. Ji, Q. Wang, Y. Li, and Z. Wang, “Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis,” Tumor Biology, vol. 35, no. 3, pp. 2787–2793, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Maeda, S.-M. Kang, M. Ogawa et al., “Combined analysis of vascular endothelial growth factor and platelet—derived endothelial cell growth factor expression in gastric carcinoma,” International Journal of Cancer, vol. 74, no. 5, pp. 545–550, 1997. View at Google Scholar · View at Scopus
  15. H. Saito, S. Tsujitani, A. Kondo, M. Ikeguchi, M. Maeta, and N. Kaibara, “Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma,” Surgery, vol. 125, no. 2, pp. 195–201, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Wang, X. Chen, J. Fang, and C. Yang, “Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth,” International Journal of Clinical and Experimental Pathology, vol. 6, no. 4, pp. 586–597, 2013. View at Google Scholar · View at Scopus
  17. H. Y. Seo, J. M. Park, K. H. Park et al., “Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients,” Japanese Journal of Clinical Oncology, vol. 40, no. 12, Article ID hyq111, pp. 1147–1153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Blank, C. Deck, L. Dreikhausen et al., “Angiogenic and growth factors in gastric cancer,” Journal of Surgical Research, vol. 194, no. 2, pp. 420–429, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Li, F. Liu, P. Sun et al., “Correlations between serum levels of vascular endothelial growth factor and endostatin with clinical pathological characteristics of patients with gastrointestinal cancers,” Hepato-Gastroenterology, vol. 59, no. 118, pp. 1865–1868, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Fushida, K. Oyama, J. Kinoshita et al., “VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody,” OncoTargets and Therapy, vol. 6, pp. 1445–1451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Y. Oh, H.-C. Kwon, S. H. Kim et al., “Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy,” Chemotherapy, vol. 58, no. 6, pp. 426–434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Villarejo-Campos, D. Padilla-Valverde, R. M. Martin et al., “Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer,” Clinical and Translational Oncology, vol. 15, no. 4, pp. 265–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Liu, Q. Zhou, Y. Lu et al., “Serum levels of endostatin and VEGF in non-small cell lung cancer patients and the relationship with the clinical pathophysiological characteristics,” Chinese Journal of Lung Cancer, vol. 7, no. 1, pp. 50–54, 2004. View at Google Scholar · View at Scopus
  24. M. Kitamura, M. Toi, K. Arai, Y. Iwasaki, H. Suzuki, and K. Matsuo, “Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients,” Oncology Reports, vol. 5, no. 6, pp. 1419–1424, 1998. View at Google Scholar · View at Scopus
  25. X. Liang, F. Xu, X. Li, C. Ma, Y. Zhang, and W. Xu, “VEGF signal system: the application of antiangiogenesis,” Current Medicinal Chemistry, vol. 21, no. 7, pp. 894–910, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Chen, X. Zhang, J. Peng et al., “VEGF promotes gastric cancer development by upregulating CRMP4,” Oncotarget, vol. 7, no. 13, pp. 17074–17086, 2016. View at Publisher · View at Google Scholar
  28. M. Scartozzi, C. Loretelli, E. Galizia et al., “Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients,” PLoS ONE, vol. 7, no. 7, Article ID e38192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Scartozzi, R. Giampieri, C. Loretelli et al., “Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients,” Pharmacogenomics, vol. 14, no. 16, pp. 1991–1998, 2013. View at Publisher · View at Google Scholar · View at Scopus